Table 1.

Summary of investigations evaluating impact of molecular testing on surgical management and outcomes.

Series	Study duration	Publication year	Test	Design	Number of patients	Impact of molecular testing
Aragon Han, P. et al. (43)	2009–2013	2014	GEC, Mutation Panel	Retrospective	87	78/87 (90%) no change in management 9/87 (10%) surgical plan altered 6/9 (67%) change inappropriate 5/6 (83%) inappropriately overtreated
Noureldine, S. et al. (44)	2012–2014	2015	GEC	Retrospective	273	250/273 (92%) no change in management 23/273 (8%) surgical plan altered 16/23 (73%) inappropriately overtreated
Marti, J. et al. (22)	2013–2014	2015	GEC	Retrospective	165	At cancer center: 42/70 (60%) GEC suspicious lesions resected 18/42 (43%) GEC suspicious resected lesions ultimately benign (inappropriately overtreated) At general hospital: 21/34 (62%) GEC suspicious lesions resected 18/21 (86%) GEC suspicious resected lesions ultimately benign (inappropriately overtreated)
Noureldine, S. et al. (45)	2014–2015	2016	GEC, ThyroSeq, Mutation Panel	Prospective	140	129/140 (92%) no change in management 11/140 (8%) surgical plan altered 10/11 (91%) inappropriately overtreated
Taye, A. et al. (28)	2014–2016	2018	ThyroSeq	Retrospective	156	37/51 (73%) ThyroSeq suspicious lesions resected 29/37 (78%) ThyroSeq suspicious resected lesions ultimately benign (inappropriately overtreated)